Moderate to high dose cyclophosphamide and intercalated Corynebacterium parvum in patients with metastatic lung cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108058
Title:
Moderate to high dose cyclophosphamide and intercalated Corynebacterium parvum in patients with metastatic lung cancer.
Authors:
Thatcher, Nick; Honeybourne, D; Wagstaff, John; Carroll, K B; Barber, Philip V; Morrison, J B; Crowther, Derek
Abstract:
Thirty-nine patients with histologically proven widely metastatic bronchogenic carcinoma were treated with cyclophosphamide and Corynebacterium parvum. The dosage of cyclophosphamide was higher than conventional as previous work had indicated better results with increased dosage. Experimental work had suggested that the addition of Corynebacterium parvum would increase the antitumour effect and possibly reduce the cyclophosphamide induced granulocytopenia. A short treatment programme using three i.v. injections of cyclophosphamide, 1.5 g/m2, 2.5 g/m2 then 3.5 g/m2, at 3 week intervals were given. Four days after each cyclophosphamide injection, C. parvum 2 mg/m2 i.v. was administered. An overall 38% tumour response rate was observed, 18% for patients with non-small-cell carcinoma and 65% for small-cell carcinoma patients. The median survival for the 39 patients was 5 months (range 1-16+ months). These results, particularly for the non-small-cell patient group are comparable to those obtained with intensive combination chemotherapy regimens administered intermittently over much longer periods. An important consideration, objectively assessed in the present study, was the effect of treatment on quality of life and breathlessness. Improvement was noted not only in those patients with tumour response but also in a proportion of those who did not fulfil the criteria of response. Toxicity was also carefully assessed and, although the cyclophosphamide dosages were higher than conventionally used, no undue problems were noted. The addition of C. parvum did not have any noticeable beneficial effect. Cyclophosphamide given at dosages higher than is usual but which do not require bone marrow rescue is worthy of further study.
Affiliation:
The Manchester Lung Tumour Group; Cancer Research Campaign Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, UK.
Citation:
Moderate to high dose cyclophosphamide and intercalated Corynebacterium parvum in patients with metastatic lung cancer. 1984, 78 (1):89-97 Br J Dis Chest
Journal:
British Journal of Diseases of the Chest
Issue Date:
Jan-1984
URI:
http://hdl.handle.net/10541/108058
DOI:
10.1016/0007-0971(84)90101-3
PubMed ID:
6318791
Type:
Article
Language:
en
ISSN:
0007-0971
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorThatcher, Nicken
dc.contributor.authorHoneybourne, Den
dc.contributor.authorWagstaff, Johnen
dc.contributor.authorCarroll, K Ben
dc.contributor.authorBarber, Philip Ven
dc.contributor.authorMorrison, J Ben
dc.contributor.authorCrowther, Dereken
dc.date.accessioned2010-07-21T12:16:12Z-
dc.date.available2010-07-21T12:16:12Z-
dc.date.issued1984-01-
dc.identifier.citationModerate to high dose cyclophosphamide and intercalated Corynebacterium parvum in patients with metastatic lung cancer. 1984, 78 (1):89-97 Br J Dis Chesten
dc.identifier.issn0007-0971-
dc.identifier.pmid6318791-
dc.identifier.doi10.1016/0007-0971(84)90101-3-
dc.identifier.urihttp://hdl.handle.net/10541/108058-
dc.description.abstractThirty-nine patients with histologically proven widely metastatic bronchogenic carcinoma were treated with cyclophosphamide and Corynebacterium parvum. The dosage of cyclophosphamide was higher than conventional as previous work had indicated better results with increased dosage. Experimental work had suggested that the addition of Corynebacterium parvum would increase the antitumour effect and possibly reduce the cyclophosphamide induced granulocytopenia. A short treatment programme using three i.v. injections of cyclophosphamide, 1.5 g/m2, 2.5 g/m2 then 3.5 g/m2, at 3 week intervals were given. Four days after each cyclophosphamide injection, C. parvum 2 mg/m2 i.v. was administered. An overall 38% tumour response rate was observed, 18% for patients with non-small-cell carcinoma and 65% for small-cell carcinoma patients. The median survival for the 39 patients was 5 months (range 1-16+ months). These results, particularly for the non-small-cell patient group are comparable to those obtained with intensive combination chemotherapy regimens administered intermittently over much longer periods. An important consideration, objectively assessed in the present study, was the effect of treatment on quality of life and breathlessness. Improvement was noted not only in those patients with tumour response but also in a proportion of those who did not fulfil the criteria of response. Toxicity was also carefully assessed and, although the cyclophosphamide dosages were higher than conventionally used, no undue problems were noted. The addition of C. parvum did not have any noticeable beneficial effect. Cyclophosphamide given at dosages higher than is usual but which do not require bone marrow rescue is worthy of further study.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subjectCancer Metastasisen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAgranulocytosis-
dc.subject.meshBacterial Vaccines-
dc.subject.meshCarcinoma, Small Cell-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshCyclophosphamide-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshPropionibacterium acnes-
dc.titleModerate to high dose cyclophosphamide and intercalated Corynebacterium parvum in patients with metastatic lung cancer.en
dc.typeArticleen
dc.contributor.departmentThe Manchester Lung Tumour Group; Cancer Research Campaign Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, UK.en
dc.identifier.journalBritish Journal of Diseases of the Chesten

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.